Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FluMos-v2
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VRC-FLUMOS0116-00-VP (FluMos-v2) is an experimental mosaic hexavalent influenza vaccine developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine utilizes a self-assembling nanoparticle platform to display hemagglutinin (HA) proteins from six different influenza virus strains (mosaic display). This design is intended to elicit a broader and more durable immune response against a wide range of influenza A and B viruses compared to traditional seasonal vaccines. It is currently being evaluated in Phase I clinical trials, such as VRC 328, to assess its safety, tolerability, and immunogenicity when administered alone or in combination with the ALFQ adjuvant.
- Other names
- FluMos-v2FluMos-v-2FluMos-v 2Mosaic Hexavalent Influenza Vaccine
02
Targets
HA-NP (Influenza A and B hemagglutinin ectodomains displayed on a nanoparticle)BCR (B-cell receptor (BCR) specific for influenza hemagglutinin epitopes)
Beyond the preview
Go deeper on FluMos-v2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FluMos-v2.